Market Overview:
The global levodopa market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as an increase in the prevalence of Parkinson’s disease, rising geriatric population, and increasing R&D investments for new drug development. Based on purity, the global levodopa market can be segmented into 98% and 99% purity segments. The 99% purity segment is expected to grow at a higher CAGR than the 98% purity segment during the forecast period from 2018 to 2030. This growth can be attributed to an increase in demand for high-purity levodopa products due to their superior quality and performance over lower-purity products. Based on application, the global levodopa market can be divided into tablet products, capsule products, and others (including powder form and injectable form).
Product Definition:
Levodopa is a medication used to treat Parkinson's disease. Levodopa helps to increase levels of dopamine in the brain, which is important for movement control.
Purity: 98%:
Purity: 98%, it's usage.
The global levodopa market size was valued at USD 8.6 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period. Increasing prevalence of Parkinson’s disease (PD) coupled with rising awareness about its treatment options are some key factors driving the industry growth.
Purity: 99%:
Purity: 99% is a drug product manufactured by the Caris Life Sciences Inc. It is used to treat patients suffering from severe motor and non-motor Parkinson's disease, as well as essential tremors. The drug has no known side effects and hence it can be administered without any restrictions.
Application Insights:
Based on application, the global levodopa market is segmented into tablet products, capsule products and others. The tablet products segment dominated the overall market in terms of revenue in 2017. This can be attributed to increasing demand for tablets as a substitute for oral dyskinesia medication that were previously available only in liquid form. Levodopa capsules are used to treat Parkinson¢â‚¬â„¢s disease symptoms such as muscle stiffness and rigidity, slow movement and abnormal movements (akathisia). These symptoms often occur along with other medical conditions including depression or dementia which may require additional treatment by a doctor.
The others segment includes product usage outside of Parkinson¢â‚¬â„¢s disease such as dystonia, Huntington's disease and Tourette syndrome among others where levodopa is used either alone or together with another drug to manage their symptoms.
Regional Analysis:
North America dominated the global levodopa market in 2017. The presence of key manufacturers and suppliers, availability of advanced technologies for manufacturing drugs, high patient awareness levels coupled with relatively higher healthcare expenditure in this region are some factors responsible for its large share. In addition, increasing R&D activities to manufacture new formulations and improve existing ones is also expected to drive the market growth over the forecast period.
Asia Pacific is anticipated to witness a lucrative CAGR during the forecast period owing to rising disposable income resulting into increased demand for various types of medication including dopamine agonists such as levodopa/carbidopa products among patients suffering from Parkinson’s disease (PD). Moreover, growing medical tourism industry due to low treatment cost along with government initiatives encouraging people from developing countries will boost regional growth further.
Growth Factors:
- Increasing prevalence of Parkinson's disease (PD) across the globe is expected to drive the levodopa market growth. According to a study by World Health Organization (WHO), PD affects about 6.3 million people worldwide and this number is anticipated to grow in future due to increasing aging population.
- Levodopa therapy is considered as gold standard for treatment of PD and thus, increasing adoption of levodopa therapy is another key factor driving the market growth.
- Availability of generic versions of levodopa drugs at lower prices is also propelling the market growth as it offers affordability options for patients suffering from PD. For instance, Sinemet CR (carbidopa/levodopa) drug, which was launched in 2016 by Merck & Co., Inc., offers a cost-effective treatment option for patients with PD in U.S..
- . Rising research and development activities aimed at developing novel therapies for treating PD are also expected to boost the demand for levodopa in coming years . For instance, In July 2017, University College London announced that it has developed a new gene therapy approach which could help improve symptoms associated with advanced stages of Parkinson's disease.. 5 . Growing awareness about available treatment options for managing PD among patients and healthcare professionals is also anticipated to fuel demand for levodOPA during forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Levodopa Market Research Report
By Type
Purity: 98%, Purity: 99%
By Application
Tablet Products, Capsule Products, Others
By Companies
Shandong Xinhua Pharmaceutical Co, Ajinomoto, Daiichi Sankyo Chemical Pharma Co, Delmar Chemicals Inc, Divis Laboratories Ltd, Egis Pharmaceuticals Private Ltd, Hangzhou Longshine Bio-Tech Co, Hoffmann La Roche Inc, Suzhou Ryway Biotech, Teva Pharmaceutical Industries Ltd, Shandong Xinhua Pharmaceutical Co, Zhejiang Huahai Pharmaceutical Co, Zhejiang Wild Wind Pharmaceutical, Broahony Group, Lanpharma Chemical Co
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
165
Number of Tables & Figures
116
Customization Available
Yes, the report can be customized as per your need.
Global Levodopa Market Report Segments:
The global Levodopa market is segmented on the basis of:
Types
Purity: 98%, Purity: 99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tablet Products, Capsule Products, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Shandong Xinhua Pharmaceutical Co
- Ajinomoto
- Daiichi Sankyo Chemical Pharma Co
- Delmar Chemicals Inc
- Divis Laboratories Ltd
- Egis Pharmaceuticals Private Ltd
- Hangzhou Longshine Bio-Tech Co
- Hoffmann La Roche Inc
- Suzhou Ryway Biotech
- Teva Pharmaceutical Industries Ltd
- Shandong Xinhua Pharmaceutical Co
- Zhejiang Huahai Pharmaceutical Co
- Zhejiang Wild Wind Pharmaceutical
- Broahony Group
- Lanpharma Chemical Co
Highlights of The Levodopa Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity: 98%
- Purity: 99%
- By Application:
- Tablet Products
- Capsule Products
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Levodopa Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Levodopa is a medication used to treat Parkinson's disease. Levodopa helps to improve the symptoms of the disease by reducing the amount of dopamine in the brain.
Some of the major companies in the levodopa market are Shandong Xinhua Pharmaceutical Co, Ajinomoto, Daiichi Sankyo Chemical Pharma Co, Delmar Chemicals Inc, Divis Laboratories Ltd, Egis Pharmaceuticals Private Ltd, Hangzhou Longshine Bio-Tech Co, Hoffmann La Roche Inc, Suzhou Ryway Biotech, Teva Pharmaceutical Industries Ltd, Shandong Xinhua Pharmaceutical Co, Zhejiang Huahai Pharmaceutical Co, Zhejiang Wild Wind Pharmaceutical, Broahony Group, Lanpharma Chemical Co.
The levodopa market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Levodopa Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Levodopa Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Levodopa Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Levodopa Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Levodopa Market Size & Forecast, 2018-2028
4.5.1 Levodopa Market Size and Y-o-Y Growth
4.5.2 Levodopa Market Absolute $ Opportunity
Chapter 5 Global Levodopa Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Levodopa Market Size Forecast by Type
5.2.1 Purity: 98%
5.2.2 Purity: 99%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Levodopa Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Levodopa Market Size Forecast by Applications
6.2.1 Tablet Products
6.2.2 Capsule Products
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Levodopa Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Levodopa Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Levodopa Analysis and Forecast
9.1 Introduction
9.2 North America Levodopa Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Levodopa Market Size Forecast by Type
9.6.1 Purity: 98%
9.6.2 Purity: 99%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Levodopa Market Size Forecast by Applications
9.10.1 Tablet Products
9.10.2 Capsule Products
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Levodopa Analysis and Forecast
10.1 Introduction
10.2 Europe Levodopa Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Levodopa Market Size Forecast by Type
10.6.1 Purity: 98%
10.6.2 Purity: 99%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Levodopa Market Size Forecast by Applications
10.10.1 Tablet Products
10.10.2 Capsule Products
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Levodopa Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Levodopa Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Levodopa Market Size Forecast by Type
11.6.1 Purity: 98%
11.6.2 Purity: 99%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Levodopa Market Size Forecast by Applications
11.10.1 Tablet Products
11.10.2 Capsule Products
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Levodopa Analysis and Forecast
12.1 Introduction
12.2 Latin America Levodopa Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Levodopa Market Size Forecast by Type
12.6.1 Purity: 98%
12.6.2 Purity: 99%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Levodopa Market Size Forecast by Applications
12.10.1 Tablet Products
12.10.2 Capsule Products
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Levodopa Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Levodopa Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Levodopa Market Size Forecast by Type
13.6.1 Purity: 98%
13.6.2 Purity: 99%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Levodopa Market Size Forecast by Applications
13.10.1 Tablet Products
13.10.2 Capsule Products
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Levodopa Market: Competitive Dashboard
14.2 Global Levodopa Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Shandong Xinhua Pharmaceutical Co
14.3.2 Ajinomoto
14.3.3 Daiichi Sankyo Chemical Pharma Co
14.3.4 Delmar Chemicals Inc
14.3.5 Divis Laboratories Ltd
14.3.6 Egis Pharmaceuticals Private Ltd
14.3.7 Hangzhou Longshine Bio-Tech Co
14.3.8 Hoffmann La Roche Inc
14.3.9 Suzhou Ryway Biotech
14.3.10 Teva Pharmaceutical Industries Ltd
14.3.11 Shandong Xinhua Pharmaceutical Co
14.3.12 Zhejiang Huahai Pharmaceutical Co
14.3.13 Zhejiang Wild Wind Pharmaceutical
14.3.14 Broahony Group
14.3.15 Lanpharma Chemical Co
